Vertex Pharmaceuticals IncorporatedVRTX
ASignal's systematic analysis rates VRTX as Neutral. Vertex Pharmaceuticals Incorporated has a market cap of $121.71B, a P/E of 28.48, a 35.5% net margin, and 7.8% year-over-year revenue growth.
Reflects the latest available analysis · analyzed Jul 16, 2026
The case on VRTX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong free cash flow of $2.78B
- Exceptional return on equity at 24.20%
- Low debt-to-equity ratio of 0.10x
- High gross margin of 54.39%
- Positive operating cash flow of $4.24B
- Current price near Bollinger Lower Band, suggesting potential reversal
- Negative price momentum of -0.09
- MACD below signal line with negative histogram
- No Reddit mentions indicating low retail sentiment visibility
- PEG ratio of 1.71x suggests overvaluation relative to growth
Key facts
Peers
Clustered with VRTX by analysis-profile similarity.
See the full verdict on VRTX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes VRTX
Most investors never get a second opinion, let alone several. ASignal runs VRTX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.